Epilepsy study hopes to predict who will get better — and why
NCT ID NCT05374928
First seen Jun 22, 2026 · Last updated Jun 22, 2026
Summary
This completed study followed 316 people with idiopathic generalized epilepsy, including those newly diagnosed and those already known to respond or not respond to treatment. Researchers collected data from seizure diaries, fitness trackers, quality-of-life surveys, and cognitive tests, along with blood and genetic samples. The goal was to find biological markers that could predict whether someone's epilepsy will go into remission, helping patients make informed decisions about driving, pregnancy, and daily life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC GENERALIZED EPILEPSY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Georgetown University
Washington D.C., District of Columbia, 20057, United States
-
Maine Medical Center
Portland, Maine, 04102, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Mid-Atlantic Epilepsy Sleep Center
Bethesda, Maryland, 20817, United States
-
Minnesota Epilepsy Group
Saint Paul, Minnesota, 55113, United States
-
Monash University
Melbourne, Clayton VIC, 3800, Australia
-
Mount Sinai Hospital
New York, New York, 10029, United States
-
NYU Langone Health - Comprehensive Epilepsy Center (CEC)
New York, New York, 10016, United States
-
Northwell Health
New York, New York, 10065, United States
-
St. Barnabas Medical Center
Livingston, New Jersey, 07039, United States
-
The Johns Hopkins Hospital
Baltimore, Maryland, 21287, United States
-
University of California San Francisco (UCSF)
San Francisco, California, 94143, United States
-
University of Miami
Miami, Florida, 33146, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
University of Texas Health Science Center
San Antonio, Texas, 77030, United States
-
University of Utah Hospital
Salt Lake City, Utah, 84132, United States
-
Washington University
St Louis, Missouri, 63130, United States
-
Yale University
New Haven, Connecticut, 06520, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this study could identify biological markers that help doctors predict how well a person with generalized epilepsy will respond to treatment, leading to more personalized care.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly test a new therapy. The findings may take years to translate into clinical practice and might not apply to all epilepsy types.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.